M&T Bank Corp Has $1.16 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

M&T Bank Corp lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 51.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,934 shares of the company's stock after purchasing an additional 8,786 shares during the period. M&T Bank Corp owned approximately 0.06% of Omnicell worth $1,155,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of OMCL. Victory Capital Management Inc. lifted its holdings in Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after buying an additional 377,883 shares in the last quarter. Keybank National Association OH raised its position in shares of Omnicell by 32.1% during the fourth quarter. Keybank National Association OH now owns 8,902 shares of the company's stock worth $396,000 after acquiring an additional 2,161 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Omnicell by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company's stock valued at $27,431,000 after acquiring an additional 21,157 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after acquiring an additional 273 shares during the last quarter. Finally, Wakefield Asset Management LLLP acquired a new stake in Omnicell in the fourth quarter worth about $1,051,000. 97.70% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms have issued reports on OMCL. StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Thursday, March 6th. Benchmark restated a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co. increased their price target on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Finally, Wells Fargo & Company decreased their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $52.33.

Omnicell Stock Down 3.2 %

Shares of OMCL stock traded down $1.06 during trading hours on Thursday, hitting $32.28. 752,380 shares of the company were exchanged, compared to its average volume of 495,094. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The business has a 50 day moving average of $40.96 and a two-hundred day moving average of $43.38. The company has a market capitalization of $1.51 billion, a PE ratio of 119.56, a PEG ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.